{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:35:21Z","timestamp":1794573321720,"version":"4.9.1"},"reference-count":239,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,18]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Immunotherapies, such as allogeneic hematopoietic cell transplantation and infusion of chimeric antigen receptor (CAR) T cells have significantly extended our therapeutic armamentarium against several hematologic malignancies. Blocking negative regulators of immunity with immune checkpoint inhibitors has significantly improved the survival of patients with mainly solid tumors. Despite their beneficial effects, these therapies are also associated with severe, immune-mediated side effects. Here, we discuss biological similarities and differences of acute graft-versus-host disease (GVHD), cytokine release syndrome, immune effector cell\u2013associated neurotoxicity syndrome, immune effector cell\u2013associated hemophagocytic lymphohistiocytosis\u2013like syndrome, immune effector cell\u2013associated hematotoxicity, local immune effector cell\u2013associated toxicity syndrome, and immune-related adverse events after immune checkpoint inhibition (irAEs). Recent data have led to a better understanding of the role of myeloid cells and T cells, including tissue-resident T cells, in the pathophysiology of GVHD, CAR T-cell\u2013associated immunotoxicities, and irAEs. Furthermore, we summarize approved, currently evaluated, and potential future therapies for immune-mediated toxicities of cancer immunotherapies. This review will help to understand how therapeutic strategies target communalities of different side effects to overcome immune-mediated side effects of cancer immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030059","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:02:41Z","timestamp":1773079361000},"page":"3001-3024","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Immune-mediated side effects of cancer immunotherapies"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0770-4994","authenticated-orcid":false,"given":"Lukas M.","family":"Braun","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany"},{"name":"2German Cancer Consortium, Partner Site Freiburg, a partnership between Deutsches Krebsforschungszentrum and Medical Center, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"3Beaumont RCSI Cancer Centre, Dublin, Ireland"},{"name":"4Beaumont Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany"},{"name":"2German Cancer Consortium, Partner Site Freiburg, a partnership between Deutsches Krebsforschungszentrum and Medical Center, University of Freiburg, Freiburg, Germany"},{"name":"5Signalling Research Centers BIOSS and CIBSS, Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9674","key":"2026061811222005200_bib1","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"2026061811222005200_bib2","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1097\/HS9.0000000000000581","article-title":"Immunomodulatory therapies for the treatment of graft-versus-host disease","volume":"5","author":"Braun","year":"2021","journal-title":"Hemasphere"},{"issue":"5","key":"2026061811222005200_bib3","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"issue":"1","key":"2026061811222005200_bib4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2026061811222005200_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"2026061811222005200_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"16","key":"2026061811222005200_bib7","doi-asserted-by":"crossref","first-page":"e177460","DOI":"10.1172\/JCI177460","article-title":"Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice","volume":"134","author":"Talvard-Balland","year":"2024","journal-title":"J Clin Invest"},{"issue":"429","key":"2026061811222005200_bib8","doi-asserted-by":"crossref","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci Transl Med"},{"issue":"1","key":"2026061811222005200_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15","key":"2026061811222005200_bib10","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"2026061811222005200_bib11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/bjh.19007","article-title":"Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response","volume":"203","author":"Apostolova","year":"2023","journal-title":"Br J Haematol"},{"issue":"22","key":"2026061811222005200_bib12","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2026061811222005200_bib13","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2026061811222005200_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2026061811222005200_bib15","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2026061811222005200_bib16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nm.3517","article-title":"Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage","volume":"20","author":"Schwab","year":"2014","journal-title":"Nat Med"},{"key":"2026061811222005200_bib17","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"6","key":"2026061811222005200_bib18","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026061811222005200_bib19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-024-01119-2","article-title":"Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management","volume":"14","author":"Khurana","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026061811222005200_bib20","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"2026061811222005200_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2026061811222005200_bib22","first-page":"438.e1","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"26","key":"2026061811222005200_bib23","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2026061811222005200_bib24","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"16","key":"2026061811222005200_bib25","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"35","key":"2026061811222005200_bib26","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026061811222005200_bib27","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"issue":"2","key":"2026061811222005200_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2026061811222005200_bib29","doi-asserted-by":"crossref","first-page":"1396490","DOI":"10.3389\/fonc.2024.1396490","article-title":"Mechanisms and management of CAR T toxicity","volume":"14","author":"Ferreri","year":"2024","journal-title":"Front Oncol"},{"issue":"21","key":"2026061811222005200_bib30","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.3390\/cancers15215149","article-title":"Immune effector cell-associated HLH-like syndrome: a review of the literature of an increasingly recognized entity","volume":"15","author":"Fugere","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026061811222005200_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"24","key":"2026061811222005200_bib32","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2026061811222005200_bib33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2026061811222005200_bib34","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1182\/blood-2024-208307","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) for chimeric antigen receptor T-cell therapy (CAR-T) and T-cell engager antibody (TCE) in myeloma and lymphoma [abstract]","volume":"144","author":"Ayoobkhan","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026061811222005200_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"24","key":"2026061811222005200_bib36","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2026061811222005200_bib37","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026061811222005200_bib38","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"2026061811222005200_bib39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2026061811222005200_bib40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1056\/NEJMc1912274","article-title":"Extracorporeal photopheresis for colitis induced by checkpoint-inhibitor therapy","volume":"382","author":"Apostolova","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2026061811222005200_bib41","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"issue":"5","key":"2026061811222005200_bib42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"751","key":"2026061811222005200_bib43","doi-asserted-by":"crossref","first-page":"eadj9672","DOI":"10.1126\/scitranslmed.adj9672","article-title":"Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation","volume":"16","author":"Vinnakota","year":"2024","journal-title":"Sci Transl Med"},{"issue":"11","key":"2026061811222005200_bib44","doi-asserted-by":"crossref","first-page":"e010158","DOI":"10.1136\/jitc-2024-010158","article-title":"Correlation of safety and efficacy of atezolizumab therapy across indications","volume":"12","author":"Duran-Pacheco","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"10","key":"2026061811222005200_bib45","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"2026061811222005200_bib46","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"2026061811222005200_bib47","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"2026061811222005200_bib48","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3390\/biomedicines10071737","article-title":"Anti-PD-1 monotherapy in advanced melanoma-real-world data from a 77-month-long retrospective observational study","volume":"10","author":"Kuzmanovszki","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"2026061811222005200_bib49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"issue":"21","key":"2026061811222005200_bib50","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"2026061811222005200_bib51","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2026061811222005200_bib52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1172\/JCI119606","article-title":"Perforin\/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation","volume":"100","author":"Graubert","year":"1997","journal-title":"J Clin Invest"},{"issue":"6","key":"2026061811222005200_bib53","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1084\/jem.183.6.2645","article-title":"The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice","volume":"183","author":"Baker","year":"1996","journal-title":"J Exp Med"},{"key":"2026061811222005200_bib54","doi-asserted-by":"crossref","first-page":"761448","DOI":"10.3389\/fimmu.2021.761448","article-title":"T cell subsets in graft versus host disease and graft versus tumor","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"2026061811222005200_bib55","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2006-12-063982","article-title":"IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract","volume":"110","author":"Burman","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2026061811222005200_bib56","doi-asserted-by":"crossref","first-page":"e20210417","DOI":"10.1084\/jem.20210417","article-title":"Human resident memory T cells exit the skin and mediate systemic Th2-driven inflammation","volume":"218","author":"Strobl","year":"2021","journal-title":"J Exp Med"},{"issue":"570","key":"2026061811222005200_bib57","doi-asserted-by":"crossref","first-page":"eabb7028","DOI":"10.1126\/scitranslmed.abb7028","article-title":"Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease","volume":"12","author":"Strobl","year":"2020","journal-title":"Sci Transl Med"},{"issue":"9","key":"2026061811222005200_bib58","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1172\/JCI129965","article-title":"Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease","volume":"130","author":"Divito","year":"2020","journal-title":"J Clin Invest"},{"issue":"67","key":"2026061811222005200_bib59","doi-asserted-by":"crossref","first-page":"eabe2634","DOI":"10.1126\/sciimmunol.abe2634","article-title":"Human skin-resident host T cells can persist long term after allogeneic stem cell transplantation and maintain recirculation potential","volume":"7","author":"de Almeida","year":"2022","journal-title":"Sci Immunol"},{"issue":"2","key":"2026061811222005200_bib60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.immuni.2023.01.003","article-title":"Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells","volume":"56","author":"Sacirbegovic","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"2026061811222005200_bib61","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41467-024-55227-5","article-title":"STAT1 regulates immune-mediated intestinal stem cell proliferation and epithelial regeneration","volume":"16","author":"Takashima","year":"2025","journal-title":"Nat Commun"},{"issue":"7","key":"2026061811222005200_bib62","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2006-04-016410","article-title":"Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse","volume":"109","author":"Chen","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2026061811222005200_bib63","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.20150329","article-title":"Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease","volume":"212","author":"Koyama","year":"2015","journal-title":"J Exp Med"},{"issue":"1","key":"2026061811222005200_bib64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI17601","article-title":"Memory CD4+ T cells do not induce graft-versus-host disease","volume":"112","author":"Anderson","year":"2003","journal-title":"J Clin Invest"},{"issue":"11","key":"2026061811222005200_bib65","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood.2022015734","article-title":"A unique immune signature in blood separates therapy-refractory from therapy-responsive acute graft-versus-host disease","volume":"141","author":"van Halteren","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026061811222005200_bib66","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1182\/blood-2004-12-4726","article-title":"Leukocyte migration and graft-versus-host disease","volume":"105","author":"Wysocki","year":"2005","journal-title":"Blood"},{"key":"2026061811222005200_bib67","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1182\/blood-2003-03-0957","article-title":"LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease","volume":"103","author":"Petrovic","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2026061811222005200_bib68","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2005-08-3445","article-title":"Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine","volume":"107","author":"Waldman","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2026061811222005200_bib69","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2007-09-112789","article-title":"Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs","volume":"111","author":"Beilhack","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2026061811222005200_bib70","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.immuni.2019.06.003","article-title":"T cell recruitment to the intestinal stem cell compartment drives immune-mediated intestinal damage after allogeneic transplantation","volume":"51","author":"Fu","year":"2019","journal-title":"Immunity"},{"issue":"9","key":"2026061811222005200_bib71","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bbmt.2009.05.003","article-title":"Up-regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation","volume":"15","author":"Chen","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2026061811222005200_bib72","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/bmt.2012.191","article-title":"Expression of alpha4beta7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD","volume":"48","author":"Chen","year":"2013","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"2026061811222005200_bib73","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1182\/blood-2008-08-172155","article-title":"IL-17 contributes to CD4-mediated graft-versus-host disease","volume":"113","author":"Kappel","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2026061811222005200_bib74","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2007-12-126987","article-title":"Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease","volume":"112","author":"Yi","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2026061811222005200_bib75","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood-2009-11-256495","article-title":"Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma","volume":"116","author":"Hill","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2026061811222005200_bib76","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/bmt.2009.223","article-title":"IL-21 is critical for GVHD in a mouse model","volume":"45","author":"Meguro","year":"2010","journal-title":"Bone Marrow Transpl"},{"issue":"26","key":"2026061811222005200_bib77","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1182\/blood-2009-05-221135","article-title":"IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation","volume":"114","author":"Bucher","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2026061811222005200_bib78","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2010-07-294785","article-title":"Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL","volume":"118","author":"Hanash","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2026061811222005200_bib79","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3904\/kjim.2025.010","article-title":"Decreased frequency and inflammatory change of FoxP3+ regulatory T cells in immunopathogenesis of human acute graft-versus-host disease","volume":"40","author":"Seong","year":"2025","journal-title":"Korean J Intern Med"},{"issue":"25","key":"2026061811222005200_bib80","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"2026061811222005200_bib81","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"43","key":"2026061811222005200_bib82","doi-asserted-by":"crossref","first-page":"eaax7969","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci Immunol"},{"issue":"8","key":"2026061811222005200_bib83","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"issue":"2","key":"2026061811222005200_bib84","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/jcbfm.2010.103","article-title":"Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study","volume":"31","author":"Galea","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"issue":"11","key":"2026061811222005200_bib85","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"2026061811222005200_bib86","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2026061811222005200_bib87","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2026061811222005200_bib88","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/2643-3230.BCD-21-0177","article-title":"Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma","volume":"3","author":"Saini","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"18","key":"2026061811222005200_bib89","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2012-05-432906","article-title":"Interferon-\u03b3 impairs proliferation of hematopoietic stem cells in mice","volume":"121","author":"de Bruin","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2026061811222005200_bib90","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood.2022017015","article-title":"Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL","volume":"140","author":"Rejeski","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2026061811222005200_bib91","doi-asserted-by":"crossref","first-page":"101158","DOI":"10.1016\/j.xcrm.2023.101158","article-title":"Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNgamma-expressing CD8 T cells","volume":"4","author":"Strati","year":"2023","journal-title":"Cell Rep Med"},{"issue":"8","key":"2026061811222005200_bib92","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1080\/10428194.2022.2056172","article-title":"Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms","volume":"63","author":"Brudno","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"2026061811222005200_bib93","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2026061811222005200_bib94","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"38","key":"2026061811222005200_bib95","doi-asserted-by":"crossref","first-page":"eadg3919","DOI":"10.1126\/sciadv.adg3919","article-title":"Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion","volume":"9","author":"Rejeski","year":"2023","journal-title":"Sci Adv"},{"issue":"2","key":"2026061811222005200_bib96","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/gtc.12742","article-title":"Diphthamide modification of eEF2 is required for gut tumor-like hyperplasia induced by oncogenic Ras","volume":"25","author":"Tsuda-Sakurai","year":"2020","journal-title":"Genes Cells"},{"issue":"3","key":"2026061811222005200_bib97","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.hoc.2025.02.005","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS)","volume":"39","author":"Lee","year":"2025","journal-title":"Hematol Oncol Clin North Am"},{"issue":"suppl 1","key":"2026061811222005200_bib98","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2023-178283","article-title":"CD22 CAR T cell-related IEC-HS is associated with an IFN-\u03b3 cytokine signature [abstract]","volume":"142","author":"Srinagesh","year":"2023","journal-title":"Blood"},{"issue":"18","key":"2026061811222005200_bib99","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","article-title":"Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"26","author":"Faramand","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2026061811222005200_bib100","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026061811222005200_bib101","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2026061811222005200_bib102","first-page":"292.e1","article-title":"Immune effector cell-associated HLH-like syndrome (IEC-HS) in CAR-T and TCE-treated myeloma and B-cell malignancies: insights from a Pharmacovigilance Study","volume":"32","author":"Irfan","year":"2026","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2026061811222005200_bib103","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J Exp Med"},{"issue":"6029","key":"2026061811222005200_bib104","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"issue":"2","key":"2026061811222005200_bib105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"3","key":"2026061811222005200_bib106","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.molmed.2024.09.009","article-title":"Immune-mediated colitis after immune checkpoint inhibitor therapy","volume":"31","author":"Giesler","year":"2025","journal-title":"Trends Mol Med"},{"issue":"2","key":"2026061811222005200_bib107","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.smim.2011.01.007","article-title":"T cell receptor recognition of self and foreign antigens in the induction of autoimmunity","volume":"23","author":"Wucherpfennig","year":"2011","journal-title":"Semin Immunol"},{"key":"2026061811222005200_bib108","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1146\/annurev-immunol-020711-075043","article-title":"Induced CD4+Foxp3+ regulatory T cells in immune tolerance","volume":"30","author":"Bilate","year":"2012","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"2026061811222005200_bib109","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"issue":"4","key":"2026061811222005200_bib110","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"2026061811222005200_bib111","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ccell.2025.01.004","article-title":"Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity","volume":"43","author":"Braun","year":"2025","journal-title":"Cancer Cell"},{"key":"2026061811222005200_bib112","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ccell.2024.04.010","article-title":"Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis","volume":"42","author":"Gupta","year":"2024","journal-title":"Cancer Cell"},{"issue":"2","key":"2026061811222005200_bib113","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10620-022-07598-2","article-title":"CD8(+) lymphocyte infiltration is a specific feature of colitis induced by immune checkpoint inhibitors","volume":"68","author":"Takahashi","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2026061811222005200_bib114","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/2326-6066.CIR-22-0362","article-title":"Checkpoint blockade-induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1\/Tc1 cytokines","volume":"10","author":"Reschke","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"2026061811222005200_bib115","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.trecan.2025.07.005","article-title":"Clinical perspective and treatment of immune-related colitis after cancer immunotherapy","volume":"11","author":"Braun","year":"2025","journal-title":"Trends Cancer"},{"issue":"6","key":"2026061811222005200_bib116","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"issue":"1","key":"2026061811222005200_bib117","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2026061811222005200_bib118","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12915-020-00784-6","article-title":"A mutation that blocks integrin alpha(4)beta(7) activation prevents adaptive immune-mediated colitis without increasing susceptibility to innate colitis","volume":"18","author":"Zhang","year":"2020","journal-title":"BMC Biol"},{"issue":"20","key":"2026061811222005200_bib119","doi-asserted-by":"crossref","first-page":"e176567","DOI":"10.1172\/JCI176567","article-title":"Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures","volume":"134","author":"Kao","year":"2024","journal-title":"J Clin Invest"},{"issue":"9","key":"2026061811222005200_bib120","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s43018-024-00810-4","article-title":"A targetable type III immune response with increase of IL-17A expressing CD4(+) T cells is associated with immunotherapy-induced toxicity in melanoma","volume":"5","author":"Dimitriou","year":"2024","journal-title":"Nat Cancer"},{"issue":"6","key":"2026061811222005200_bib121","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"2026061811222005200_bib122","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo","volume":"194","author":"Das","year":"2015","journal-title":"J Immunol"},{"issue":"4","key":"2026061811222005200_bib123","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"issue":"1","key":"2026061811222005200_bib124","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jhep.2021.02.008","article-title":"Activation and transcriptional profile of monocytes and CD8(+) T cells are altered in checkpoint inhibitor-related hepatitis","volume":"75","author":"Gudd","year":"2021","journal-title":"J Hepatol"},{"issue":"7937","key":"2026061811222005200_bib125","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for alpha-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"issue":"13","key":"2026061811222005200_bib126","doi-asserted-by":"crossref","first-page":"e188843","DOI":"10.1172\/jci.insight.188843","article-title":"Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy","volume":"10","author":"Huang","year":"2025","journal-title":"JCI Insight"},{"issue":"12","key":"2026061811222005200_bib127","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.4049\/jimmunol.1501357","article-title":"A novel function for P2Y2 in myeloid recipient-derived cells during graft-versus-host disease","volume":"195","author":"Klambt","year":"2015","journal-title":"J Immunol"},{"issue":"9","key":"2026061811222005200_bib128","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1172\/JCI133909","article-title":"Donor monocyte-derived macrophages promote human acute graft-versus-host disease","volume":"130","author":"Jardine","year":"2020","journal-title":"J Clin Invest"},{"issue":"5","key":"2026061811222005200_bib129","first-page":"248.e1","article-title":"Calprotectin expressing donor-derived macrophages increase in acute gastrointestinal graft-versus-host disease","volume":"28","author":"Aasebo","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2026061811222005200_bib130","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/bjd\/ljad402","article-title":"Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease","volume":"190","author":"Strobl","year":"2024","journal-title":"Br J Dermatol"},{"issue":"16","key":"2026061811222005200_bib131","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood-2017-10-812891","article-title":"Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset","volume":"131","author":"Hulsdunker","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2026061811222005200_bib132","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm1089","article-title":"Donor APCs are required for maximal GVHD but not for GVL","volume":"10","author":"Matte","year":"2004","journal-title":"Nat Med"},{"issue":"6","key":"2026061811222005200_bib133","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nm0602-575","article-title":"Acute graft-versus-host disease does not require alloantigen expression on host epithelium","volume":"8","author":"Teshima","year":"2002","journal-title":"Nat Med"},{"issue":"5426","key":"2026061811222005200_bib134","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1126\/science.285.5426.412","article-title":"Prevention of graft versus host disease by inactivation of host antigen-presenting cells","volume":"285","author":"Shlomchik","year":"1999","journal-title":"Science"},{"issue":"735","key":"2026061811222005200_bib135","doi-asserted-by":"crossref","first-page":"eadi1501","DOI":"10.1126\/scitranslmed.adi1501","article-title":"Lipocalin-2 expression identifies an intestinal regulatory neutrophil population during acute graft-versus-host disease","volume":"16","author":"Czech","year":"2024","journal-title":"Sci Transl Med"},{"issue":"10","key":"2026061811222005200_bib136","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1084\/jem.20130084","article-title":"The Nlrp3 inflammasome regulates acute graft-versus-host disease","volume":"210","author":"Jankovic","year":"2013","journal-title":"J Exp Med"},{"issue":"3","key":"2026061811222005200_bib137","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1172\/JCI130272","article-title":"Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia","volume":"130","author":"Mathew","year":"2020","journal-title":"J Clin Invest"},{"issue":"6","key":"2026061811222005200_bib138","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"2026061811222005200_bib139","doi-asserted-by":"crossref","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"issue":"17","key":"2026061811222005200_bib140","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","article-title":"Comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome patients with B-cell ALL receiving CAR T19","volume":"28","author":"Diorio","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2026061811222005200_bib141","first-page":"430","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"2026061811222005200_bib142","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"5","key":"2026061811222005200_bib143","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2026061811222005200_bib144","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41419-021-03428-x","article-title":"DAMPs released by pyroptotic cells as major contributors and therapeutic targets for CAR-T-related toxicities","volume":"12","author":"Deng","year":"2021","journal-title":"Cell Death Dis"},{"issue":"2","key":"2026061811222005200_bib145","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bjh.18747","article-title":"Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy","volume":"202","author":"Kitamura","year":"2023","journal-title":"Br J Haematol"},{"issue":"14","key":"2026061811222005200_bib146","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","article-title":"Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators","volume":"294","author":"Sachdeva","year":"2019","journal-title":"J Biol Chem"},{"issue":"7","key":"2026061811222005200_bib147","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"issue":"1-4","key":"2026061811222005200_bib148","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbrc.2018.11.021","article-title":"IFN-gamma, IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: relevance for neuro-inflammatory diseases","volume":"507","author":"Rahman","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"2026061811222005200_bib149","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"2026061811222005200_bib150","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/s43018-024-00764-7","article-title":"Targeting TGFbeta-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome","volume":"5","author":"Vinnakota","year":"2024","journal-title":"Nat Cancer"},{"issue":"12","key":"2026061811222005200_bib151","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1016\/j.cell.2025.03.041","article-title":"Immunotherapy-related cognitive impairment after CAR T cell therapy in mice","volume":"188","author":"Geraghty","year":"2025","journal-title":"Cell"},{"issue":"1","key":"2026061811222005200_bib152","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol"},{"issue":"2","key":"2026061811222005200_bib153","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1073858413504466","article-title":"Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators","volume":"20","author":"Sofroniew","year":"2014","journal-title":"Neuroscientist"},{"issue":"2","key":"2026061811222005200_bib154","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.medj.2022.12.007","article-title":"Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors","volume":"4","author":"Nunez","year":"2023","journal-title":"Med"},{"issue":"1","key":"2026061811222005200_bib155","doi-asserted-by":"crossref","first-page":"e002058","DOI":"10.1136\/jitc-2020-002058","article-title":"Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2026061811222005200_bib156","doi-asserted-by":"crossref","first-page":"10733","DOI":"10.1038\/s41467-024-54180-7","article-title":"Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"2026061811222005200_bib157","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"key":"2026061811222005200_bib158","doi-asserted-by":"crossref","first-page":"987568","DOI":"10.3389\/fimmu.2022.987568","article-title":"Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"2026061811222005200_bib159","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J Clin Invest"},{"issue":"3","key":"2026061811222005200_bib160","doi-asserted-by":"crossref","first-page":"e008482","DOI":"10.1136\/jitc-2023-008482","article-title":"Inhibition of IL-25\/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity","volume":"12","author":"Hu","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"24","key":"2026061811222005200_bib161","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2026061811222005200_bib162","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1038\/leu.2017.137","article-title":"MicroRNA-146a reduces MHC-II expression via targeting JAK\/STAT signaling in dendritic cells after stem cell transplantation","volume":"31","author":"Stickel","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"2026061811222005200_bib163","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"issue":"19","key":"2026061811222005200_bib164","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2026061811222005200_bib165","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"2026061811222005200_bib166","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1053\/j.gastro.2020.10.029","article-title":"Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis","volume":"160","author":"Bishu","year":"2021","journal-title":"Gastroenterology"},{"issue":"10","key":"2026061811222005200_bib167","first-page":"e70032","article-title":"JAK inhibitor upadacitinib induces remission in refractory immune-related colitis triggered by CTLA-4 and PD-1 inhibitor combination therapy in malignant pleural mesothelioma: a case report","volume":"7","author":"Kono","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"issue":"2","key":"2026061811222005200_bib168","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00277-024-05952-0","article-title":"Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease","volume":"104","author":"Kujawska","year":"2025","journal-title":"Ann Hematol"},{"issue":"3","key":"2026061811222005200_bib169","doi-asserted-by":"crossref","first-page":"E88","DOI":"10.1002\/ajh.26077","article-title":"Fecal microbiota transplantation in patients with acute and chronic graft-versus-host disease-spectrum of responses and safety profile. Results from a prospective, multicenter study","volume":"96","author":"Bilinski","year":"2021","journal-title":"Am J Hematol"},{"issue":"6529","key":"2026061811222005200_bib170","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"issue":"12","key":"2026061811222005200_bib171","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"2026061811222005200_bib172","first-page":"272.e1","article-title":"Vedolizumab for steroid refractory lower gastrointestinal tract graft-versus-host disease","volume":"27","author":"Mehta","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2026061811222005200_bib173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0484-x","article-title":"Complete response of metastatic melanoma in a patient with Crohn\u2019s disease simultaneously receiving anti-\u03b14\u03b27 and anti-PD1 antibodies","volume":"7","author":"Frohne","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2026061811222005200_bib174","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41409-020-01188-4","article-title":"Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD","volume":"56","author":"Mehta","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"2026061811222005200_bib175","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41409-020-01122-8","article-title":"Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease","volume":"56","author":"Maas-Bauer","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2026061811222005200_bib176","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2026061811222005200_bib177","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch Melanoma Treatment Registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026061811222005200_bib178","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41409-018-0236-z","article-title":"Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract","volume":"54","author":"Ganetsky","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2026061811222005200_bib179","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"issue":"7","key":"2026061811222005200_bib180","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"key":"2026061811222005200_bib181","doi-asserted-by":"crossref","first-page":"1241068","DOI":"10.3389\/fimmu.2023.1241068","article-title":"Novel therapies for graft versus host disease with a focus on cell therapies","volume":"14","author":"Zeiser","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"2026061811222005200_bib182","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood.2020005957","article-title":"Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans","volume":"136","author":"Norona","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2026061811222005200_bib183","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41409-025-02586-2","article-title":"Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey","volume":"60","author":"Brehm","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2026061811222005200_bib184","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kroger","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2026061811222005200_bib185","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"2026061811222005200_bib186","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood-2016-09-738625","article-title":"A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD","volume":"129","author":"Socie","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2026061811222005200_bib187","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41409-020-0855-z","article-title":"Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody-Begelomab","volume":"55","author":"Bacigalupo","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"2026061811222005200_bib188","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1038\/s41591-024-03016-4","article-title":"Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial","volume":"30","author":"Chen","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"2026061811222005200_bib189","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/sctm.17-0167","article-title":"Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease","volume":"7","author":"Ringden","year":"2018","journal-title":"Stem Cells Transl Med"},{"issue":"12","key":"2026061811222005200_bib190","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood.2021015111","article-title":"A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract","volume":"141","author":"Ponce","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026061811222005200_bib191","first-page":"509.e1","article-title":"Phase II, open-label clinical trial of urinary-derived human chorionic gonadotropin\/epidermal growth factor for life-threatening acute graft-versus-host disease","volume":"29","author":"Holtan","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"7","key":"2026061811222005200_bib192","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/bloodadvances.2019001259","article-title":"Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor","volume":"4","author":"Holtan","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2026061811222005200_bib193","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"20","key":"2026061811222005200_bib194","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026061811222005200_bib195","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2026061811222005200_bib196","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/hematology.2023000435","article-title":"Managing side effects: guidance for use of immunotherapies in multiple myeloma","volume":"2023","author":"Liang","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"2026061811222005200_bib197","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12967-024-05063-4","article-title":"CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude","volume":"22","author":"Poiret","year":"2024","journal-title":"J Transl Med"},{"issue":"23","key":"2026061811222005200_bib198","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"issue":"26","key":"2026061811222005200_bib199","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"2026061811222005200_bib200","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2026061811222005200_bib201","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2026061811222005200_bib202","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-024-01100-5","article-title":"Novel strategies to manage CAR-T cell toxicity","volume":"24","author":"Mulvey","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"575","key":"2026061811222005200_bib203","doi-asserted-by":"crossref","first-page":"eabb6295","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci Transl Med"},{"issue":"18","key":"2026061811222005200_bib204","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"issue":"5319","key":"2026061811222005200_bib205","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science"},{"issue":"9","key":"2026061811222005200_bib206","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"2026061811222005200_bib207","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/10430340460732463","article-title":"Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease","volume":"15","author":"Serafini","year":"2004","journal-title":"Hum Gene Ther"},{"issue":"5","key":"2026061811222005200_bib208","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjh.18454","article-title":"Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel","volume":"199","author":"Porter","year":"2022","journal-title":"Br J Haematol"},{"issue":"24","key":"2026061811222005200_bib209","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2026061811222005200_bib210","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"7906","key":"2026061811222005200_bib211","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"issue":"1","key":"2026061811222005200_bib212","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFNgamma improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"2026061811222005200_bib213","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFNgamma reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"801","key":"2026061811222005200_bib214","doi-asserted-by":"crossref","first-page":"eadp8166","DOI":"10.1126\/scitranslmed.adp8166","article-title":"IFN-gamma-resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models","volume":"17","author":"Bailey","year":"2025","journal-title":"Sci Transl Med"},{"issue":"9","key":"2026061811222005200_bib215","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","article-title":"IFNgamma is critical for CAR T cell-mediated myeloid activation and induction of endogenous immunity","volume":"11","author":"Alizadeh","year":"2021","journal-title":"Cancer Discov"},{"issue":"17","key":"2026061811222005200_bib216","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2026061811222005200_bib217","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"16","key":"2026061811222005200_bib218","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/bloodadvances.2022007776","article-title":"Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy","volume":"6","author":"Rejeski","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2026061811222005200_bib219","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","article-title":"Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA\/DRST study","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2026061811222005200_bib220","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"2026061811222005200_bib221","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"36","key":"2026061811222005200_bib222","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7756","key":"2026061811222005200_bib223","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"issue":"1","key":"2026061811222005200_bib224","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.it.2024.11.014","article-title":"Targeting molecular pathways to control immune checkpoint inhibitor toxicities","volume":"46","author":"Reschke","year":"2025","journal-title":"Trends Immunol"},{"issue":"9","key":"2026061811222005200_bib225","doi-asserted-by":"crossref","first-page":"e005111","DOI":"10.1136\/jitc-2022-005111","article-title":"COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2026061811222005200_bib226","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/s41467-024-46195-x","article-title":"Single-cell profiling identifies IL1B(hi) macrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"2026061811222005200_bib227","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/1078-0432.CCR-20-1610","article-title":"Blocking IL1 beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: multidimensional analyses","volume":"27","author":"Aggen","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2026061811222005200_bib228","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1056\/NEJMc2002527","article-title":"Tofacitinib for refractory immune-related colitis from PD-1 therapy","volume":"382","author":"Esfahani","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2026061811222005200_bib229","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"issue":"5","key":"2026061811222005200_bib230","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"issue":"3","key":"2026061811222005200_bib231","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2326-6066.CIR-23-0498","article-title":"Immune-related colitis is associated with fecal microbial dysbiosis and can be mitigated by fecal microbiota transplantation","volume":"12","author":"Elkrief","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2026061811222005200_bib232","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"12","key":"2026061811222005200_bib233","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3324\/haematol.2017.171157","article-title":"Steroid treatment of acute graft-versus-host disease grade I: a randomized trial","volume":"102","author":"Bacigalupo","year":"2017","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026061811222005200_bib234","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2024-198360","article-title":"Safety and efficacy of the glucagon-like peptide 2 (GLP-2) analog apraglutide in patients with steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD) in combination with best available therapy: results from a multicenter, randomized, single-blind, proof-of-concept, phase 2 stargaze trial [abstract]","volume":"144","author":"Zeiser","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026061811222005200_bib235","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"issue":"21","key":"2026061811222005200_bib236","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1182\/bloodadvances.2023010653","article-title":"A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma","volume":"7","author":"Strati","year":"2023","journal-title":"Blood Adv"},{"key":"2026061811222005200_bib237","doi-asserted-by":"crossref","first-page":"1500177","DOI":"10.3389\/fimmu.2024.1500177","article-title":"GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation - successfully treated by extracorporeal photopheresis","volume":"15","author":"Farid","year":"2024","journal-title":"Front Immunol"},{"key":"2026061811222005200_bib238","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1182\/bloodadvances.2025015912","article-title":"GVHD in the era of checkpoint inhibition in Hodgkin lymphoma","volume":"9","author":"Fidanza","year":"2025","journal-title":"Blood Adv"},{"key":"2026061811222005200_bib239","doi-asserted-by":"crossref","first-page":"1491330","DOI":"10.3389\/fimmu.2024.1491330","article-title":"The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Hu","year":"2024","journal-title":"Front Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/25\/3001\/2528288\/blood_bld-2025-030059-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/25\/3001\/2528288\/blood_bld-2025-030059-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:22:49Z","timestamp":1781796169000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/25\/3001\/567021\/Immune-mediated-side-effects-of-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":239,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026,6,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030059","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,18]]},"published":{"date-parts":[[2026,6,18]]}}}